2상모집 중단 (진행 중)
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
연구 개요
Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation. Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months. Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.
- 스폰서
- 협력: 암젠
- 적응증
- Smoldering Multiple Myeloma
- 중재
- carfilzomib, Lenalidomide, Dexamethasone, Melphalan
- 목표 등록
- 90명
- 시작일
- 2015-05-01
- 완료(예정)
- 2027-06-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.